Enterprise Value
241.1M
Cash
400.2M
Avg Qtr Burn
-43.18M
Short % of Float
2.17%
Insider Ownership
27.88%
Institutional Own.
28.57%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EXS21546 (A2A receptor antagonist) Details Cancer, Non-small cell lung carcinoma, Renal cell carcinoma | Phase 1/2 Data readout | |
GTAEXS617 (CDK7 inhibitor) Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
EXS4318 (PKC-theta Inhibitor) Details Inflammatory disease | Phase 1 Data readout |